BRIDGEBIO PHARMA INC. - COMMON STOCK

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

05 7 2024 15:31:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

18 6 2024 06:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

10 6 2024 06:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference

06 6 2024 06:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia

04 6 2024 06:30:00 提供 Nasdaq GlobeNewswire

BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024

03 6 2024 15:01:00 提供 Nasdaq GlobeNewswire

Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

29 5 2024 15:01:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting

24 5 2024 06:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

15 5 2024 06:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024

14 5 2024 06:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population

13 5 2024 06:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update

02 5 2024 06:30:00 提供 Nasdaq GlobeNewswire

BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline

02 5 2024 06:00:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

10 4 2024 06:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

07 4 2024 12:15:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

20 3 2024 06:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Announces Pricing of Public Offering of Common Stock

05 3 2024 22:53:56 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Announces Proposed Public Offering of Common Stock

04 3 2024 15:17:36 提供 Nasdaq GlobeNewswire

BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM

04 3 2024 01:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

22 2 2024 06:30:00 提供 Nasdaq GlobeNewswire